PriceTargets.com logo

BioStem Technologies - BSEM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 125.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$4.00 As of 06/18/2026 04:51 PM ET
▲ +0.085 (2.17%)

This chart shows the closing price for BSEM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioStem Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BSEM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BSEM

Analyst Price Target is $9.00
▲ +125.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioStem Technologies in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 125.00% upside from the last price of $4.00.

This chart shows the closing price for BSEM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in BioStem Technologies. This rating has held steady since April 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/19/2026

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/6/2026HC WainwrightInitiated CoverageBuy$9.00
5/6/2026HC WainwrightUpgradeStrong-Buy
3/18/2026Zacks ResearchUpgradeHold
(Data available from 6/19/2021 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/20/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2026

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
BioStem Technologies logo
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
Read More

Today's Range

Now: $4.00
Low: $3.90
High: $4.25

50 Day Range

MA: $4.35
Low: $3.36
High: $5.20

52 Week Range

Now: $4.00
Low: $3.09
High: $13.80

Volume

20,494 shs

Average Volume

60,713 shs

Market Capitalization

$71.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

Frequently Asked Questions

What sell-side analysts currently cover shares of BioStem Technologies?

The following Wall Street sell-side analysts have issued research reports on BioStem Technologies in the last twelve months: HC Wainwright, and Zacks Research.
View the latest analyst ratings for BSEM.

What is the current price target for BioStem Technologies?

0 Wall Street analysts have set twelve-month price targets for BioStem Technologies in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 125.0%. HC Wainwright has the highest price target set, predicting BSEM will reach $9.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $9.00 for BioStem Technologies in the next year.
View the latest price targets for BSEM.

What is the current consensus analyst rating for BioStem Technologies?

BioStem Technologies currently has 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BSEM will outperform the market and that investors should add to their positions of BioStem Technologies.
View the latest ratings for BSEM.

What other companies compete with BioStem Technologies?

Other companies that are similar to BioStem Technologies include Editas Medicine, Orchestra BioMed, Alpha Teknova, Fulcrum Therapeutics and Forte Biosciences. Learn More about companies similar to BioStem Technologies.

How do I contact BioStem Technologies' investor relations team?

BioStem Technologies' physical mailing address is 2836 Center Port Circle, Pompano Beach, FL 33064, United States. The company's listed phone number is 954-380-8342. The official website for BioStem Technologies is www.biostemtechnologies.com. Learn More about contacing BioStem Technologies investor relations.